



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Summary of Main Points from the Meeting held on Monday 27th January 2020 - Draft

2. Minutes and Summary Notes from last meeting

The minutes and summary notes of the Medicines Group Meeting held on 16th January 2020 were approved. The summary notes will be disseminated and published on the Trust intranet.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

- Nil

Ex-panel

- Nil

Removals

- Nil

Other

- **Doravirine 100mg Tablets (Pifeltro[®]) (MSD)**
- **Delstrigo[®] (Doravirine 100mg / Lamivudine 300mg and Tenofovir Disoproxil Fumarate 300mg (equivalent to 245mg of Tenofovir Disoproxil)) Tablets (MSD)**

Approved by the HIV/GUM Medicines Sub-group for addition to the Trust Formulary in line with NHS England Commissioning Policy for Doravirine for the treatment of HIV-1 in adults.

Outcome: Noted

NICE Approved drug applications

- Nil

Pharmacoeconomic Board requests

- **Uridine Triacetate as an Antidote for 5FU Toxicity in Homozygote DPD deficiency**

Approved by Pharmacoeconomic Board on 27/12/2019. This was issued at a cost of £75k from WMUH Pharmacy. Pharmacy will seek to request reimbursement for the cost of this medicine from NHS England.

Outcome: Noted

4.2 Trust Medicines Policy

- **RPSGB: Professional guidance on the safe and secure handling of medicines**
 - Principles and Framework - Gap Analysis and Action Plan
 - Appendix A - Storage of medicines in health care setting - Gap Analysis and Action Plans
 - Appendix C - Operating Theatres - Gap Analysis and Action Plans
 - Risk Assessment: Pincodes on medicines storage units
 - Log of medicines not locked away with relating risk assessments
 - Risk Assessment: 10 HB: Anaphylactic kits stored unlocked
 - Risk assessment: Haemodialysis fluids stored by bedside on ITU (WMUH)



The Gap Analysis for the Principles and Framework section for the guidance was presented. Principles are fully compliant and Framework actions include: New SOPs required relating to Goods Receipt; Waste; COSHH spillages. There is also a need for electronic COSHH risk assessments and data sheets to be made available to pharmacy staff.

The Gap Analysis for Storage of medicines in health care setting (Appendix A) and Operating Theatres (Appendix B) was also presented. Areas of non-compliance have been highlighted and action plans drawn up for each ward/department. Action plans are in progress.

Risk Assessment: Pincodes on medicines storage units - This covers an assessment of the risk of maintaining key pads with shared pin codes on a number of drug trolleys, cupboards, fridges and bedside lockers that are currently in use throughout the Trust. This is linked with standard A12.2 of the guidance.

Log of medicines not locked away with relating risk assessment was noted. This will act as a register going forward. All scenarios included on log have a relating risk assessment in place which currently is in date.

Risk Assessment: 10 HB: Anaphylactic kits stored unlocked - New Risk Assessment

Risk assessment: Haemodialysis fluids stored by bedside on ITU (WMUH) - New Risk Assessment

Decision: All documents noted

- **Adult IV Administration Guide - Updates**

Updated to include:

- Zanamivir (Dectova[®]) - New Monograph as this
- Update: Flecanide (Due to procuring an unlicensed preparation)

Decision: Approved

4.3 Medicines Optimisation

- **Out-patient prescribing of new non-urgent medicines**

Feedback from out-patient prescribing of new non-urgent medicines audit undertaken by Pharmacy

Decision: Deferred until the next meeting.

4.4 NICE Technical Appraisals and Guidance

a) NICE Technical Appraisals

3 Appraisal published in December 2019

TA614 - Cannabidiol with clobazam for treating seizures associated with Dravet syndrome

Formulary status / Action

Nil action - Not applicable - CWFT not commissioned

TA615 - Cannabidiol with clobazam for treating seizures associated with Lennox - Gastaut syndrome

Formulary status / Action

Nil action - Not applicable - CWFT not commissioned

TA616 - Cladribine for treating relapsing - remitting multiple sclerosis

1.2 This recommendation is not intended to affect treatment with cladribine that was started in the NHS before

Formulary status / Action

CWFT not currently commissioned - Clinical Commissioning Pharmacist following this up with NHS England as would expect Secondary Centres to be commissioned if Primary Centre is commissioned. ICHT is approved for commissioning.

1 Appraisal published in January 2020



TA617 - Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Formulary status / Action
Nil action - Not applicable - CWFT not commissioned

b) NICE Highly Specialised Technologies
1 Highly Specialised Technologies published in January 2020

HST12 - Cerliponase alfa for treating neuronal ceroid lipofuscinosis Type 2
Formulary status / Action
Nil action - Not applicable - CWFT not commissioned

4.5 IVIG requests

- **IVIG Issues for December 2019 - CWH Site**

There were 9 IVIG issues in December 2019, with 4 new requests:

Decision: Approved

- **IVIG Issues for December 2019 - WMUH Site**

There were 13 IVIG issues in December 2019, with 2 new requests:

Decision: Approved

4.6 Items for noting

- **RMOC Guidance re Vitamin B**

RMOC Guidance on Vitamin B for the prevention of Wernicke's Encephalopathy (WE) in alcoholism.
Published November 2019.

Decision: Noted

- **Medication Shortage Log - January**

Medication Shortage Log for January

Decision: Noted

- **Medicines Safety bulletin - Prescribing errors and how to prevent them**

Medicines Safety Bulletin re Prescribing errors and how to prevent them - Published November 2019

Decision: Noted

- **Medicines Safety bulletin - Adrenaline Auto-injectors**

Medicines Safety Bulletin re Adrenaline Auto-Injectors - Published December 2019

Decision: Noted

- **MHRA Drug Safety Update - December 2019**

MHRA update for October 2019

Decision: Noted

4.7 Meeting minutes for noting



- **HIV/GUM Directorate - Medicines Sub-Group Meeting - November 2019**

Minutes from HIV/GUM Directorate - Medicines Sub-Group meeting - November 2019

Decision: Noted

- **Medication Safety Group - December 2019**

Minutes from Medication safety Group meeting - January 2020

Decision: Noted

4.8 Additional papers to go to Trust Patient Safety Group

Nil

5. Any other business

Issues relating to Insulins on Cerner

It was raised that all insulins listed on Cerner have not been set up with the route of administration defaulted to subcutaneous (SC). Levemir/Detemir insulin is the only insulin that has been identified that has this field defaulted on Cerner. Concerns have been expressed that while the route of administration of all other insulins remain defaulted there is a risk that the incorrect route may be selected by the prescriber.

In addition, when prescribing insulins on Cerner there is a choice of frequency to choose from on a drop down menu. For the prandial insulins, the frequency of administration is detailed as TDS / BD. MF has requested that the listed options for prandial insulins are updated accordingly to reflect meal times e.g. Before/With meal - which may be once, twice or three times per day depending on the number of meals eaten per day.

6. Date of next meeting

Date: 23th March

Time: 8am-9am

Location: Main Boardroom (CWH) and meeting room A (WMUH)

Closing date: 5th March 2020